Here are four quick facts about the rating, as reported by Financial Market News.
1. Two equities research analysts gave Accretive Health’s stock a “hold” rating, while another analyst issued a “strong buy” rating on the company.
2. Accretive Health’s rating score has improved by 22.3 percent from three months ago due to numerous analysts’ ratings changes.
3. Analysts have a consensus one-year price target of $4.50 for the company and expect Accretive Health to post $0.08 earnings per share for the current quarter, according to Zacks.
4. The company has a 12-month low of $1.77 and a 12-month high of $6.30.
More articles on finance and revenue cycle management:
For-profit hospital stock report: Week of Feb. 15-19
OIG: Connecticut hospital received $249k in Medicare overpayments
Medicare spending spikes due to lengthy hospice care: 5 things to know
